ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA
Clinical trials for ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo shows promise against Tough-to-Treat lymphoma
Disease control CompletedThis study tested a combination of the targeted drug brentuximab vedotin (ADCETRIS) plus standard CHP chemotherapy in 82 people with newly diagnosed peripheral T-cell lymphoma (PTCL) that has low CD30 levels. The goal was to see how many patients' tumors shrank or disappeared. Re…
Matched conditions: ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Experimental drug shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis study tested a drug called brentuximab vedotin in 23 people with a type of T-cell lymphoma that had stopped responding to or returned after prior chemotherapy. The drug is designed to seek out and kill cancer cells that have a specific marker called CD30, even when levels of…
Matched conditions: ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Deepa Jagadeesh • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC